Article

A dose escalating, placebo controlled, double blind, single dose and multidose, safety and tolerability study of fontolizumab, a humanised anti-interferon gamma antibody, in patients with moderate to severe Crohn's disease.

Universitaetsklinik Innere Medizin IV, Abteilung Gastroenterologie and Hepatologie, Vienna, Austria.
Gut (Impact Factor: 13.32). 09/2006; 55(8):1138-44. DOI: 10.1136/gut.2005.079434
Source: PubMed

ABSTRACT This study was designed to evaluate the safety of fontolizumab, a humanised anti-interferon gamma antibody, in patients with moderate to severe Crohn's disease (CD).
Forty five patients with a CD activity index (CDAI) of 250-450 were randomised in a double blind, placebo controlled, dose escalating fashion to receive single doses of fontolizumab (0.1, 1.0, and 4.0 mg/kg) or placebo. By day 29, patients with clinical response were re-randomised to receive three additional doses of one half their initial fontolizumab dose or placebo at four weekly intervals. Primary objectives were safety and tolerability. Secondary outcomes included assessments of immunogenicity, clinical activity, and potential pharmacodynamic surrogates.
Treatment was generally well tolerated. There were slightly more reports of chills, flu-like syndrome, asthenia, nausea, and vomiting in the 1.0 mg and 4.0 mg/kg fontolizumab cohorts. Two serious adverse events rated as worsening of CD occurred under fontolizumab. Antibodies to fontolizumab were confirmed in one patient. No differences in clinical activity parameters were noted between any of the active treatment groups and placebo, with the placebo group having a particularly favourable outcome (60% response and 40% remission). By day 29, a more enhanced decrease in median Crohn's disease endoscopic index of severity (p = 0.02) and serum C reactive protein (p<0.001) was observed in the 4.0 mg/kg (n = 14) fontolizumab cohort compared with placebo (n = 10). Pharmacodynamic effects were observed by immunohistochemistry.
Fontolizumab was well tolerated with minimal immunogenicity at doses of up to 4.0 mg/kg in patients with CD. A biological activity of fontolizumab is suggested.

Full-text

Available from: Karel Geboes, May 29, 2015
0 Followers
 · 
228 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Significant advances have been made during the past decade in the understanding of autoimmune diseases and in the development of therapeutics targeting various immune pathways. T-cell-mediated immune dysregulation occurs in a variety of autoimmune conditions, including rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis. Inhibition of the T-cell function using CTLA-4Ig is currently approved for management of rheumatoid arthritis. Select therapies targeting adhesion molecules are used for the management of patients with psoriasis and multiple sclerosis. Therapeutics targeting tumor necrosis factor-α (TNF-α), a cytokine secreted by T cells, is widely used in patients with rheumatoid arthritis and inflammatory bowel disease. Furthermore, several therapies target a variety of molecules related to T cells that are under development or undergoing clinical trials. Drug Dev Res 72:585–597, 2011. © 2011 Wiley Periodicals, Inc.
    Drug Development Research 11/2011; 72(7). DOI:10.1002/ddr.20468 · 0.73 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: It is important to have clear goals for treating inflammatory bowel disease in clinical practice and in research. Conventional endpoints for trials in ulcerative colitis (UC) and Crohn’s disease (CD) have been based on composite indices, such as the Mayo Clinic Score and the Crohn’s Disease Activity Index; these incorporate symptoms, signs, and findings from laboratory tests and sometimes endoscopic assessments. Although definitions of clinical response and remission have been based on these indices for regulatory purposes, the indices are difficult to apply to practice—they are complex and not intuitive to clinicians. This has caused a disconnect between clinical trials and practice. Recently, the use of composite indices in trials has been reevaluated in Food and Drug Administration-sponsored Gastroenterology Regulatory Endpoints and Advancement of Therapeutics workshops, due to concerns about the validity of the indices. Alternative measures of outcome and definitions of response are being developed. Patient-reported outcomes (PROs) are psychometric instruments created and defined by patients to quantify symptoms. A combination of endpoints, comprising PRO and objective evaluation of inflammation by endoscopy, offers a clinically meaningful and scientifically valid alternative to existing composite indices. Unlike composite indices, response definitions based on endoscopy and PROs can be readily applied in practice. This convergence of outcome assessment in clinical trials and practice could expedite implementation of “treat to target” algorithms, in which therapy is progressively intensified until a specific treatment goal is reached. This approach could improve patient care by reducing rates of disease-related complications, surgery, and hospitalization.
    Gastroenterology 08/2014; 148(1). DOI:10.1053/j.gastro.2014.08.003 · 13.93 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Anti-TNF- α agents emerge as the hot spot in the last decade in treatment for inflammatory bowel disease (IBD). The effect of anti TNF- α agents is satisfactory, however, some patients failed to achieve clinical response due to these agents. Fortunately, in recent years, a great deal of invention and development has been made and multiple novel therapies have been developed in the treatment for IBD. In this study, we aim to introduce anti-TNF- α drugs as well as other novel treatment currently undergoing clinical trial for IBD.
    Journal of Digestive Diseases 09/2014; 15(11). DOI:10.1111/1751-2980.12193 · 1.92 Impact Factor